Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.68 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283205 | 0.88 | EGFR (0.70) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL8930320 | 0.88 | PARP10 (0.69) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL1557011 | 0.87 | FFAR1 (0.71) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL6811506 | 0.87 | EGFR (0.69) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL2088706 | 0.86 | NR4A2 (0.70) | EGFRNR4A2FFAR1FFAR4MAOB | |
| SCHEMBL4152328 | 0.86 | EGFR (0.72) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL27517502 | 0.86 | EGFR (0.68) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL9718167 | 0.85 | NR4A1 (0.70) | EGFRNR4A2NR4A1NR4A3FFAR1 | |
| SCHEMBL2087540 | 0.84 | NR4A2 (0.73) | NR4A2FFAR1MAOBPARP10 | |
| SCHEMBL11290489 | 0.84 | EGFR (0.66) | EGFRNR4A2NR4A1NR4A3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| CN-101969773-A | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-02-09 | — | — | CN | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| CN-100344616-C | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2007-10-24 | — | — | CN | claimed |
| CN-1608055-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2005-04-20 | — | — | CN | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | EGFR 3857/4885NR4A2 2849/4885NR4A1 2933/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | EGFR 2760/4885NR4A2 1494/4885NR4A1 621/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | EGFR 4498/4885NR4A2 1952/4885NR4A1 2981/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | EGFR 3857/4885NR4A2 2849/4885NR4A1 2933/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | EGFR 3857/4885NR4A2 2849/4885NR4A1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.